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Abstract. – Dupuytren’s disease is a fibro-
proliferative condition involving the superficial
palmar fascia, leading to a progressive and irre-
versible flexion of the fingers. In literature, there
are different opinions regarding the phenobarbi-
tal, a common antiepileptic drug, and its effec-
tive role in the genesis and development of
Dupuytren’s disease.
In this retrospective investigation the associ-
ation between phenobarbital and Dupuytren’s
contracture is discussed.Three patients in
treatment with phenobarbital who had no oth-
ers significant risk factors for Dupuytren’s con-
tracture were included in this study. The dis-
ease occurred after one to four years of drug
therapy, at dosage of 100 mg/day. After surgery,
Dupuytren’s disease showed different evolutions
in relation to dosage and type of antiepileptic
drug used.
Phenobarbital causes a dose and time-dipen-
dent profibrotic effect. A clinical regression was
observed when phenobarbital was substituted
by carbamazepine, maintaining the same dosage
(100 mg/day). This data confirms that not all the
antiepileptic drugs are implicated in palmar fi-
brosis, and suggests that, according to the effi-
cacy and adverse effects, the administration of
benzodiazepine reduces the risk of Dupuytren’s
recurrence.
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Introduction
Dupuytren’s disease is a fibroproliferative con-
dition involving the superficial palmar fascia,
leading to a progressive and irreversible flexion
of the fingers. The aetiology of some aspects is
still unclear. Many factors are already known to
be implicated, such traumas of the hand, alcohol,
diabetes, smoking, as well as different molecular
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factors like Interleukin 1 (IL 1), free radicals and
Transforming Growth Factor-β (TGF- β)1. In re-
cent studies is discussed the role of the genetic
predisposition, demonstrating the association
with some polymorphic genes of TGF-β and its
receptor2. These studies clearly demonstrate the
complex oligogenic rather than monogenic con-
dition od Dupuytren’s disease which segregates
into multiple modes of inheritance. There are dif-
ferent opinions regarding the association with the
phenobarbital used for the antiepileptic treatment
and its effective role in the genesis and develop-
ment of Dupuytren’s disease.
Our case reports show clearly the association
between phenobarbital and Dupuytren’s contrac-
ture.
Methods
From January 2006 to December 2009, 63 pa-
tients, 41 men, 22 women with Dupuytren’s con-
tracture underwent to surgical correction in the
Department of Plastic and Reconstructive
Surgery of the University of Palermo, Italy. Nine
patients (14.2%), six women, three men, present-
ed neurological disorders in treatment with phe-
nobarbital. Among them three were manual
workers, two smoked and one patient had dia-
betes mellitus. These patients were excluded
from this investigation. At final review only three
patients in treatment with phenobarbital, who
had no other significant risk factors, were includ-
ed in the study.
Case 1
A 43-years-old man, with a familiar history of
neurologic abnormalities, affected from epilepsy
and slight mental retardation, was treated with
phenobarbital (100 mg/day) since seven years. In
the patient history the palmar contracture oc-
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At the same time, after several electroencephalo-
graphies which showed the absence of neurolog-
ic disorders, phenobarbital’s dosage was reduced
to 50 mg/day, and this therapy continued for 18
months about.
During this period we noticed a progressive,
complete resolution of the palmar fibromatosis
(Figure 4).
Case 3
A 64-year-old right hand dominant woman, in
treatment with phenobarbital (100 mg/day), after
experiencing a convulsive syndrome due to a cra-
nial trauma for a car accident she had four years
earlier. The palmar contracture developed after
two years, at the third finger of the predominant
hand, at stage II when the patient was visited. We
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curred after three years of treatment, worsing
progressively. We observed the Dupuytren’s dis-
ease bilaterally at the fourth finger: at stage III
for the left hand, at stage II for the right one (pre-
dominant) according to the Tubiana’s classifica-
tion system3, which is based on the total passive
extention deficit of each ray (stage I: 0°- 45°,
stage II: 45°-90°, stage III: 90°-135°, stage IV:
135°-180°). At the left hand we realized a Brun-
ner incision, then the selective fasciectomy. He
underwent the physical therapy (3 sessions for 30
min/week, up to 7 weeks) and put a dynamic
splint all day for two months, obtaining a signifi-
cant result in hand function and finger extension.
After three months from the operation the patient
had an aggressive recurrence with palmar skin
shrinkage, needing to carry out a full-thickness
skin graft. The disease occurred again after one
month, along the margin of the graft. The right
hand, not operated, worsened slowly to stage III.
During this period the patient did not change the
dosage of phenobarbital.
Case 2
A 49-year-old right hand dominant man, with
a history of prior cerebral ischemic episode, was
started on a drug therapy with phenobarbital (100
mg/day). After one year of treatment the palmar
fibromatosis developed at the fourth finger of the
left hand, and in few months it settled at stage II.
He underwent selective fasciectomy, applying
a Skoog incision (Figure 1), and starting, as soon
as possible, physical therapy (3 sessions for 30
min/week, up to 8 weeks with home exercises)
with the improvement of the finger extension
(Figure 2). Four months after surgery a palmar
recurrence in nodule shape occurred (Figure 3).
Figure 1. Intra-operative view.
Figure 2. Post-operative view, after two months from the
surgery.
Figure 3. The shape nodule recurrence, after three months
from the surgery.
performed a selective fasciectomy, removing the
cord and a palmar nodule. A nodule shape recur-
rence appeared at the palm after three months
from the surgery. At the same time, the neurolo-
gist replaced the phenobarbital therapy with car-
bamazepine (100 mg/day), to reduce side-effect
regarding sedation of cognitive functions. The
nodule disappeared and no other recurrence of fi-
bromatosis developed to date.
Discussion
Epilepsy is one of the most serious neurologi-
cal disorders, occurring in different types of cere-
bral lesions: head injury, stroke, cerebral arterove-
nous malformation and cerebral tumour4-5. It is
historically associated to Dupuytren’s disease.
The first description of a reliable relation was
made by Lund6. Skoog7 described a prevalence
of 42% of Dupuytren’s contracture in 207 pa-
tients treated for epilepsy. This was confirmed
by later studies8-10. Critchley et al11 in a study of
chronic epileptics recorded a 56% prevalence of
Dupuytren’s disease, symmetrical, bilateral and
associated with knuckle pads and plantar nodules.
According to James12 and Quintana Guitian13, this
percentage is much lower, between 2% and 3%,
versus 0.8% to 1.8% in the general population.
Male patients with epilepsy would be five times
more likely to develop Dupuytren’s contracture
than the population without epilepsy, in women
this risk would be 11-fold. With regard to the co-
incidence between epilepsy and palmar fibrosis
two hypotheses prevail. The first is that both these
diseases are inherited disorders; This hypothesis
is supported by the fact that tha palmar fibrosis is
often associated with the idiopathic more than
with the post-traumatic epilepsy14,15.
The second is the probable side-effect of
antiepileptic therapy. According to a study of the
collateral effects of antiepileptics on 197 pa-
tients, the frequency of Dupuytren’s disease is
7,9%, but there would be not significant differ-
ences between cases and control groups16. The
limit of this study is having included any kind of
antiepileptic drugs, while today it seems that not
all of them are implicated in the genesis of pal-
mar contracture. Phenobarbital is the most com-
monly used of barbiturate drugs. There are few
cases reported in literature about phenobarbital’s
administration and Dupuytren’s disease with
variable results. In the study of Arafa et al17, the
prevalence of Dupuytren’s disease among the
residents of two epileptic centres was analyzed.
The distribution of the disease in epileptic pa-
tients treated with phenobarbital was similar to
patients without epilepsy (control group), but the
Dupuytren’s disease process was more severe
compared to the control population. The study
suggests that phenobarbital could be associated
to Dupuytren’s contracture but this is only a
trend and not statistically significant.
Our case load demonstrates this association. In
the first patient we noticed the recurrence of pal-
mar fibrosis after three months from the first
surgery and after one month from the full-thick-
ness skin graft. This aggressive development was
directly proportional to prolonged phenopar-
bital’s administration without dose modification.
In the second case the reduction of phenobarbi-
tal’s dosage from 100 mg/day to 50 mg/day ap-
plied at early stage of a recurrence showed the
complete resolution of the palmar fibrosis. This
demonstrates that the dosage probably have a
role in the genesis of Dupuytren’s contracture
only at the proliferative stage, characterized by
nodules with proliferation of perivascular hyper-
plastic fibroblasts18. The numerous myofibrob-
lasts at the involutional stage, and the mature col-
lagen fiber stroma of the residual stage probably
are less sensitive to dosage, but we have no suffi-
cient data to confirm it.
In the third patient we noticed the clinical re-
gression of a nodule shape recurrence when phe-
nobarbital was substituted by carbamazepine,
maintaining the same dosage (100 mg/day). This
data confirms that not all the antiepileptic drugs
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Figure 4. Regression of the nodule after phenobarbital re-
placement with carbamazepine.
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are implicated in palmar fibrosis, and also sug-
gests that, according to the antiepileptic efficacy
and adverse effects, the administration of carba-
mazepine reduces the risk of Dupuytren’s recur-
rence.
Our case reports demonstrate that phenobarbi-
tal cause a dose and time-dipendent profibrotic
effect, and the carbamazepine seems to be not in-
volved in the genesis of Dupuytren’s contracture.
To date no prospective analysis has proven a sig-
nificant statistical correlation between the pheno-
barbital and the palmar fibrosis, the few retro-
spective studies are not reliable, due to the diffi-
culty to select patients without other risk factors
for Dupuytren’s disease. Many other studies are
necessary to understand if phenobarbital deter-
mines palmar fibrosis through the modulation of
the well known profibrotic biomolecular factors,
or through other unclear mechanisms. Regard to
the benzodiazepines, they are not correlated to an
increased risk of arrhythmogenic potential, sud-
den unexpected death (SUD) and abnormalities of
bone metabolism as for phenobarbital19-21. Some
trials have no found significant difference in effi-
cacy between phenobarbital and carbamazepine22.
For this reason, in presence of patients treated
with phenobarbital with an high risk to develop
the Dupuytren’s contracture or its recurrence it is
advisable his substitution with not profibrotic
antiepileptic drugs like the benzodiazepines.
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